Robert M. Centor, MD; Katherine Tuttle, MD
Disclosures: Dr. Centor has disclosed the following: Honoraria: Medscape. Dr. Tuttle has disclosed the following: Honoraria: Eli Lilly and Company. Consultantship: Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca, Gilead, and Goldfinch Bio
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.
Audio. Annals On Call - SGLT2 Inhibitors: The Good, the Bad, and the Ugly: Dr. Centor discusses the risks and benefits of using SGLT2 inhibitors to treat patients with type 2 diabetes with Dr. Katherine Tuttle, an endocrinologist and nephrologist at Washington State University.
Other Audio Options: Download MP3
Centor RM, Tuttle K. Annals On Call - SGLT2 Inhibitors: The Good, the Bad, and the Ugly. Ann Intern Med. 2019;171:OC1. doi: https://doi.org/10.7326/A19-0011
Download citation file:
Published: Ann Intern Med. 2019;171(3):OC1.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Nephrology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use